Between Jan @ , @ , and March @ , @ , we randomly assigned @ eosinophilic individuals to placebo ( n = @ ) or benralizumab @ mg dose ( n = @ ) , @ mg dose , ( n = @ ) , or @ mg dose ( n = @ ) , and @ non-eosinophilic individuals to @ mg benralizumab ( n = @ , @ included in analysis ) or placebo ( n = @ , @ included in analysis ) .